CVRx Inc. (NASDAQ: CVRX) announced that Chief Financial Officer Jared Oasheim will step down from his role to pursue other professional opportunities. The medical device company said Oasheim will remain with the company until a successor is appointed and will serve as an advisor through February 2027.

Oasheim joined CVRx in 2015 and led the company through its initial public offering. Kevin Hykes, President and Chief Executive Officer, said in a statement that Oasheim built the finance organization that supports the company's commercial growth.

"It has been a privilege to help build CVRx alongside such a dedicated team and to play a part in bringing Barostim to more patients," Oasheim said. "Taking the company public and helping establish its financial foundation has been one of the highlights of my career."

CVRx has initiated a search to identify its next Chief Financial Officer. The Minneapolis-based company develops neuromodulation solutions for patients with cardiovascular diseases.

The company also announced that Hykes and Oasheim will present at the Goldman Sachs 47th Annual Global Healthcare Conference in Miami on June 10 at 8:00 a.m. Eastern Time.

CVRx's primary product is Barostim, an implantable device that delivers electrical pulses to baroreceptors in the carotid artery wall to treat heart failure symptoms. The device has FDA approval for heart failure patients in the United States and CE Mark approval for heart failure and resistant hypertension in the European Economic Area.